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Objective: To perform a molecular mechanism-based investigation of the chondroprotective potential of
hylan G-F 20.
Method: The effects of hylan G-F 20 on IL-1b-induced glycosaminoglycan (GAG) depletion and matrix
metalloproteinase (MMP) expression in bovine and human cartilage explants were evaluated. Three
weekly intra-articular hylan G-F 20 or control injections were administered 4 weeks post-operatively to
rabbits with surgically induced osteoarthritis (OA). Cartilage histopathologic scores and osteophyte size
were evaluated at 1, 4, and 8 weeks post-injections. Histomorphometry and immunostaining were used
to quantify cartilage area and type II collagen (Col II) intensity, and real-time polymerase chain reaction
(PCR) was used to examine the mRNA levels of Col2A1, MMP-13, -16 and IL-1b at 1 week.
Results: Hylan G-F 20 retained GAG in IL-1b-exposed bovine and human cartilage explants and abrogated
IL-1b-mediated increases in MMP-1, -3, and -13 in human explant culture. Hylan G-F 20‒treated OA
joints had signiﬁcantly better cartilage integrity at 1 and 4 weeks post-treatment and signiﬁcantly
smaller osteophytes at 4 weeks compared with control. Col2A1 mRNA increased with hylan G-F 20
treatment, which correlated with a trend toward increased Col II immunostaining. MMP-13 and -16
mRNAs increased in OA cartilage, but were not signiﬁcantly altered by hylan G-F 20. IL-1b mRNA was
undetectable in cartilage and unaltered in the synovium.
Conclusions: Hylan G-F 20 improved cartilage integrity and decreased osteophyte formation in the rabbit
model of OA. Our results suggest that hylan G-F 20 may stimulate cartilage repair by increasing Col II, and
inhibit IL-1b-mediated matrix degradation by decreasing MMPs.
 2012 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Hyaluronan (HA), a natural complex sugar of the glycosamino-
glycan (GAG) family, is a long-chain polymer containing repeating
disaccharide units of glucuronic acid and N-acetylglucosamine. It is
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Elsevier Ltd on behalf of Osteoartviscoelastic properties of the normal synovial ﬂuid. Under patho-
logic conditions of osteoarthritis (OA), the concentration and the
molecular weight of HA in synovial ﬂuid markedly decrease,
leading to poor lubrication and load distribution in joints1,2.
Therefore, supplementation of the joint with exogenous HA (vis-
cosupplementation) has been proposed to restore rheological
homeostasis of OA joints3.
Intra-articular (IA) injections of HA have been used clinically to
manage OA pain for patients who have failed to respond adequately
to conservative non-pharmacologic therapy and simple analgesics.
The symptom-modifying effects of HAwith a course of three or ﬁve
injections have been reported to last over 6 months in some
patients. Accumulating evidence from clinical studies also suggests
chondroprotective potential for various HAs by showing signiﬁ-
cantly less progression of joint space narrowingwith HAvs placebo4
or standard of care5, inhibited matrix metalloproteinases (MMPs)
from synovial tissue of patients with OA6, and reduced MMP-9 inhritis Research Society International.
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have also indicated that HA treatment can decrease cartilage
degeneration in animal models of OA8e13.
Taken together, these data support the notion that HA may slow
OA disease progression in some patient populations by protecting
cartilage structural integrity. More comprehensive preclinical and
clinical data will be needed to conclusively prove this hypothesis,
and the mechanism of the potential chondroprotective effects of
viscosupplementation remains to be elucidated.
While each of these existing studies contributes data supporting
the hypothesis that HA is chondroprotective, only one of the available
preclinical studies has evaluated high molecular weight cross-linked
HA. Further, most studies focus on one time point post-admini
stration rather than a time course, and mechanistic evaluations such
as theeffects onmatrixmolecule synthesis and retentionandcatabolic
factors, such as those belonging to the MMP family, have not been
frequently included. In this study, we aimed to assess the chon-
droprotective potential of hylan G-F 20, an avian derived 6e8 MDa
divinylsulfone cross-linked HA gel/ﬂuid combination used as
a symptom-modifying therapy for OA, in a rabbit model of OA and to
examine the duration of treatment effects. More importantly, we tried
to understand the molecular mechanism of potential structural
beneﬁts of hylan G-F 20 therapy in vitro and in vivo by analyzing
expressionofgenes involved incartilagematrixmetabolisminnormal,
OA, and hylan G-F 20-treated OA cartilage, and by interrogating
commonlystudiedanabolic andcatabolicpathways.These studies aim
to provide insights into the therapeutic effects and molecular mech-
anism of high molecular weight viscosupplementation therapy.
Methods
Cartilage explant culture and treatment
Articular cartilage (AC) was harvested from the medial femoral
condyles (MFCs) of 6-month-old bovine and a 79-year-old non-
arthritic human donor. The tissues were processed to 6 mm
(diameter)  1 mm (thickness) explants using sterile techniques.
Prior to treatments, explants were maintained for 2 days in 24-well
plates, one/well, with 1.5 ml of Dulbecco’s Modiﬁed Eagles Medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (Hyclone, Logan, UT, USA) at 37C, 5% CO2, and 95% humidity.
An initial pilot study to conﬁrm IL-1b-induced GAG loss in
bovine cartilage explants was performed. In this case, one explant/
treatment condition was either left untreated or treated with IL-1b
for 3 or 6 days. Based on the results of this pilot (see Results
section), pre-treatment with IL-1b for 3e4 days was used in
subsequent studies to induce 10e20% GAG loss before hylan
treatment to mimic clinical situations. Treatments were performed
either in triplicate with one explant/well (bovine) or in single well
with two explants/well (human) in serum-free media.
Cartilage explants were pre-treated with or without 5 ng/ml of
IL-1b for 3 days (bovine) or 10 ng/ml of IL-1b for 4 days (human).
The explants were incubated with either control medium or
medium containing 0.1% (w/v) of hylan G-F 20 (Synvisc; Genzyme,
Cambridge, MA, USA) for another 3 days in the presence of IL-1b.
Since hylan G-F 20 is composed of 80% hylan A ﬂuid and 20% hylan
B gel, hylan A (0.08% w/v) and hylan B (0.02% w/v) were tested
separately in the bovine explant culture. IL-1Ra (Kineret; Amgen,
Thousand Oaks, CA, USA), at a ﬁnal concentration of 816 nM, was
used as a positive control for IL-1b inhibition. Explants and condi-
tioned medium were collected at the end of the culture period.
Cultured explants were bisected in the middle. One half was sub-
jected to Safranin-O staining, and the other half was digested and
subjected to 1,9-dimethylmethylene blue (DMMB) assay in dupli-
cate. DMMB data were normalized to cartilage wet weight.Safranin-O staining and DMMB assay of GAG
Cultured bovine and human cartilage explants were ﬁxed in 10%
formalin, bisected in themiddle, embedded in parafﬁn, and cut into
5 mm sections. GAG content was visualized using standard Safranin-
O staining14. Brieﬂy, dewaxed and hydrated sections were stained
with 2% hematoxylin for 5 min, 1.0% Safranin-O for 30 min, and
counterstained with 0.02% Fast Green for 1 min. Stained slides were
dehydrated, coverslipped and photographed.
Conditioned medium was collected from bovine cartilage
explant culture, and the presence of GAG released from explants
was quantiﬁed using dye DMMB (Polysciences, Warrington, PA,
USA). Culture medium was pre-treated with 0.5 units/ml of hyal-
uronidase (Seikagaku, Tokyo, Japan) at 37C for 3 h to remove
exogenous HA which interferes with the DMMB assay. Digests (in
duplicate) were mixed with DMMB in 96-well plates and read at
520 nm using SpectraMax 384 Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA). The amount of GAG in the condi-
tioned medium was extrapolated using chondroitin-6-sulfate C
from Shark cartilage (SigmaeAldrich, St. Louis, MO, USA) as
a standard15,16. The average values of the duplicates were normal-
ized to the wet weights of cartilage explants. The data were shown
as the mean of GAG released into the condition media from three
explants (treated in separate wells)  standard error.
Multiplex assay of human MMPs
Conditionedmediumwas collected fromhumancartilage explant
culture (two explants/well/treatment) and subjected to multiplex
analysis forMMP-1, -3 and -13 using CustomPremix FluorokineMAP
Kits (R&D Systems, Minneapolis, MN, USA). Samples and standards
were prepared according to the Manufacturer’s instructions and
analyzed using Bio-Plex 200 Systems (Bio-Rad, Hercules, CA, USA).
Each sample was tested in two different dilutions, and the values
within detection limits were shown. To control any system and
human errors, the results were repeated by re-analyzing the same
samples. The datawere shown as theMMP levels in the conditioned
media from two explants treated in the same well.
IL-1 radiobinding assay
An IL-1 radiobinding assay was performed (MDS Pharma Inc.,
Bothell, Washington) to conﬁrm that the IL-1 inhibitory effects of
hylan G-F 20 in culture were not an artifact of the viscous hylan G-F
20 solution coating the cultured explants and physically blocking
access of IL-1 to the tissues, which may occur after IA administra-
tion. Sterile bacterially sourced HA (3.0 MDa) was depolymerized
by gamma irradiation to give samples of HAwith MWs of 0.005, 0.1,
0.49, and 1.6 MDa. As described by Chin et al.,17 IL-1 receptor-
expressingmouse ﬁbroblasts were exposed inmonolayer culture to
125I-IL-1á and known concentrations of various molecular weight
HA preparations (from 0.005 to 6 MDa) for 2 h at 20C. Carboxy-
methylcellulose was used as an inert viscosity control. Following
washing and trypsinization, radioactivity of cell suspensions was
quantiﬁed and compared with the untreated control.
Experimental OA model and treatments
All animal studieswere approvedby the InstitutionalAnimal Care
and Use Committee. Ninety-six male New Zealand White rabbits
(8e12months of age; bodyweight 3.2e4.5 kg)were purchased from
Millbrook Breeding Labs (Amherst, MA, USA). One set of animals
underwent anterior cruciate ligament transection (ACLT) to induce
OA, whereas another underwent sham surgery in one randomly
selected knee. Brieﬂy, under general anesthesia and aseptic
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space, and the anterior cruciate ligament was identiﬁed, elevated
with a small hook, and completely transected. Sham surgery was
performed with an incision down to, but not penetrating, the joint
capsule. Both incisions were routinely closed with sutures. Animals
were allowed free-cage activity without joint immobilization and
were monitored for postoperative complications.
Four weeks post-operatively, a series of three IA injections were
administered once a week for 3 weeks with 0.5 ml hylan G-F 20
(0.8% w/v) or Lactated Ringer’s Solution (LRS; injection control)
administered to ACLT animals. Sham-operated animals received
LRS injections following the same schedule. Animals wereFig. 1. Hylan G-F 20 ameliorates IL-1b induced GAG loss from bovine cartilage. (A) Cartilage
explants was analyzed using Safranin-O staining (left panel) and DMMB assay (right panel).
control), hylan G-F 20 (HYL), hylan A (HYL A), hylan B (HYL B) were added in the presence o
staining. (C) GAG released into conditioned media was assayed by DMMB and normalized tosacriﬁced at 1, 4 and 8 weeks after the last injection and the
operated joints were collected for histologic analysis (n ¼ 8/group
at each time point; 72 total animals). A parallel set of animals
(n ¼ 8/group; 24 total animals) was sacriﬁced 1 week post-
injection, and cartilage and synovium were collected for real-time
polymerase chain reaction (PCR) analysis.
Osteophyte size
After sacriﬁce, rabbit jointswere openedbyan incision across the
patellar tendon to fully expose the joint space, femoral groove and
femoral condyle. Morphologic photos were taken using a digitalexplants either untreated (control) or treated with IL-1b for 3 or 6 days. GAG content in
(B/C) Cartilage explants were treated in triplicate with IL-1b for 3 days. IL-1Ra (positive
f IL-1b for another 3 days. (B) GAG content in explants was analyzed using Safranin-O
explant wet weight. *P < 0.05 vs control of IL-1b treatment (n ¼ 3 explants/treatment).
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surface for all animals. Osteophyteson theperimeter of the trochlear
ridges were recorded by tracing the area of bony growth and area
was quantiﬁed using MetaMorph image analysis software (Molec-
ularDevices,Downingtown, PA,USA). Theprocedurewasperformed
by an image analyst blinded to procedure and treatment.
Histologic assessment
Rabbit joints were immersion-ﬁxed whole in 4% para-
formaldehyde (pH 7.4) for 24 h at 4C. Two coronal cuts were made
using an Isomet saw with a diamond blade (Buehler, Lake Bluff, IL,
USA) to create three tissue blocks for parafﬁn embedding. Blocks
were ﬁxed for an additional 24 h at 4C, decalciﬁed using 29%
formic acid for 3e4 weeks, and embedded in parafﬁn. Each block
was cut into 5e8 mm sections. One randomly selected section per
block was stained with hematoxylin and eosin (H&E), and the next
serial sectionwas stained with toluidine blue by standard methods.
Histological slides were scored using the Carlson OA scoring
system18 by a board-certiﬁed pathologist that was independent of
the investigators’ research group and blinded to treatment group
designation. The Carlson scoring system was used to evaluate OA-
related histological changes in cartilage based on cartilage integ-
rity, cellularity, proteoglycan content, and tidemark (TM)18.
Histomorphometric analysis of cartilage area and thickness
Decalciﬁed jointswere analyzed for cartilage thicknessandareaby
digitalhistomorphometry.Oneof the threeH&E-stainedslide samples
from each animal was analyzed in a blinded fashion. Slides were
digitally scanned by an automated slide scanner at 4magniﬁcation.
The cartilage area was then manually traced out for each of the fourFig. 2. Hylan G-F 20 inhibits IL-1b induced GAG loss and MMP production in cultured human
20 (HYL) was added in the presence of IL-1b for another 3 days. (A) GAG content visualized
>OR (out of range) higher than the highest standard.cartilage compartments present on the obtained digital images using
measurement landmarks, which included the cruciate insertion
axially andmidwayalong thecurvature of the surface abaxially for the
lateral and MFCs. The tibial surfaces were measured axially from the
middle of the crest of the tibia to the edge of the curve of the surface
abaxially. The greatest thickness of each of the four surfaces was also
measured. Total joint area and total thicknessmeasurementswere the
sum of all four individual compartments measurements.
Collagen type II immunohistochemical staining and digital
microscopy image analysis
Deparafﬁnized sections were pre-treated with 2% testicular hyal-
uronidase (Sigma, St. Louis,MO,USA) for 30minat roomtemperature.
Sectionswere incubatedwith amouse anti-chick type II collagen (Col
II) antibody (Clone II-II6B3, Developmental Studies Hybridoma Bank,
Iowa City, IA, USA) or an isotype control antibody overnight at 4C.
Afterwashing, sectionswere incubatedwith aperoxidase-conjugated
dextran polymer visualization system (mouse Envision, DAKO, Car-
pinteria, CA, USA) for 30 min at room temperature. Slides were
developed using diaminobenzidine (DAKO, Carpinteria, CA, USA) as
chromogen and counterstained with hematoxylin.
Col II immunoreactivity was quantiﬁed using computer-assisted
digital microscopy image analysis. Immunohistochemically stained
slides were scanned using Automated Cellular Imaging System II
(ACIS II; ChromaVision Medical Systems, San Juan Capistrano, CA,
USA). Images of femorotibial joints were reconstructed using the
system software and visualized on a computer monitor19. AC of the
femoral condyle and tibial plateau was deﬁned manually based on
speciﬁc anatomical landmarks. An average signal intensity value of
Col II immunostaining in a selected ﬁeld (femur or tibia) was
generated by MetaMorph software.cartilage explants. Cartilage explants were treated with IL-1b for 4 days, and hylan G-F
by Safranin-O staining. (B) Protein levels of total MMP-1, -3, and -13 in culture media.
Fig. 3. Hylan G-F 20 suppresses osteophyte formation in OA joints. (A) Morphological
images of operated joints were taken at necropsy. a and b, femoral condyle; c and d,
femoral trochlear region. a and c, sham surgery; b and d, ACLT (OA). Arrows indicate
cartilage lesions and arrow heads indicate osteophyte formation. (B) Osteophyte area
at the medial and lateral regions of the trochlear ridge perimeter was quantiﬁed using
MetaMorph image analysis and summed as total osteophyte area. The data are
expressed as mean areas  SD (n ¼ 8 animals/group). LRS control. *P ¼ 0.041 for OA/
HYL vs OA/LRS at 4 weeks.
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AC was collected from distal femurs, proximal tibiae, and
patellae, and pooled within each animal, but not between animals.
Synovium was collected from the femorotibial joint. Tissue was
ﬂash-frozen in liquid nitrogen immediately after collection and
stored at 80C before analysis.
Frozen tissue was homogenized using a handheld high-shear
homogenizer (OMNI International, Marietta, GA, USA). Total RNA was
isolated using Trizol (Invitrogen, Carlsbad, CA, USA) and cleaned using
RNeasy column (Qiagen, Valencia, CA, USA). cDNAwas ampliﬁed from
RNA (20 ng) using the NuGen Ovation kit (San Carlos, CA, USA). Rabbit
gene-speciﬁc primers and probes were designed using Primer Express
software (AppliedBiosystems,FosterCity,CA,USA).Thegenespeciﬁcity
of the amplicons was conﬁrmed by BLASTN search (GenBank). The
following primers and probes were used: Col2A1: forward 50-
TGGCGGCTTCCACTTCA-30, reverse 50-TCTGGACGTTGGCAGTGTTG-30,
probe 50-AGACAGCAGCCTGC-30; MMP-13: forward 50-CAGATGGG
CATATCCCTCTAAGAA-30, reverse 50-TCCTCACCTTTGGTCTTTGTCTTC-30,
probe 50-ACATCATAGTCACTAAAGAC-30; MMP-16: forward 50-
CAGCACTGTGAAAGCCATAGCT-30, reverse 50-AAACCAATACAAGGAGG
CATAAGG-30, probe 50-TGTCATTCCCTGCATCT-30; IL-1b: forward 50-
CACTCCTCCGACCCTTGCT-30, reverse 50-CTGGCCTTGCCTGAATGG-30,
probe 50-AGCCAGCCTCTCTT-30. An endogenous control gene, Mus
musculus high mobility group box 1, was chosen based on our unpub-
lished microarray data, forward 50- CCCTGTCCTGGTGGTATTTTCA-30,
reverse 50-CCAATTTACAACCCCCAGACTGT-30, probe 50-TAGCCAC
TAACCTTGCC-30. PCRwas carried out in triplicate usingABI Prism7900
Sequence Detector (Applied Biosystems, Foster City, CA, USA); the
resultswereobtainedusing SDS2.1 software. Relative expression levels
of each target genewere calculatedusing2DDCtmethod20. To generate
theDCt, theCt valueof the target genewas subtracted fromtheCt value
of the endogenous control gene. The average DCt of the sham/LRS
control group (N¼ 8)wasused asbaseline and subtracted fromtheDCt
ofeachanimal togenerateDDCt.Thedatawereshownasgroupmeanof
expression levelsof targetgene standarderror (N¼8animals/group).
Statistical analyses
For in vitro studies, and rabbit OA model osteophyte area, and
cartilage area/thickness measurements, means for each group were
compared by Student’s t-test. Analysis of variance (ANOVA)was used
to analyze rabbit histologic scores with treatments, sections, and
joint surfaces being used as predictors after assuring that assump-
tions of normality and homogeneity were not violated by use of
Boxplot and normal probability plot of residuals. All samples were
randomly/independently collected. All comparisons were based on
least squaremeans(LS-means)asanestimation, afteradjusting forall
other predictors, of the marginal means for a balanced population,
since very occasionally, a few sections or joint surfaces could not be
scored due to positioning artifacts in histologic cassettes prior to
sectioning, which caused an unbalanced design. In most cases, all
sections and joint surfaces were able to be scored, and therefore no
difference between arithmetic means and LS-means was observed.
SAS8.2 (SAS Institute Inc., Cary, NC,USA)wasused to analyze all data,
and a P-value 0.05 was considered signiﬁcant.
Results
Bovine and human explant cultures
For the initial pilot study, Safranin-O staining [Fig. 1(A), left
panel], and DMMB assay [Fig. 1(A), right panel] demonstrated that
explants exposed to IL-1b showed a time-dependent decrease in
GAG content. Adding hylan G-F 20 or its ﬂuid component, hylan A,appeared to ameliorate IL-1â mediated GAG loss, as demonstrated
by the retention of Safranin-O staining [Fig. 1(B)] and a trend
toward a decrease in GAG released into conditioned media
[Fig. 1(C)] in the hylan-treated explants vs IL-1â-treated controls
(n ¼ 3 explants/treatment).
Human cartilage explants also demonstrated GAG loss with IL-1â
andGAG retentionwith hylanG-F 20 treatment in the presence of IL-
1â [Fig. 2(A)]. Protein levels of MMP-1, -3, and -13 were found to be
increased in the conditioned media from IL-1â-stimulated explants,
whichwere decreased in that fromhylan-treated explants [Fig. 2(B)].
IL-1 radiobinding assay
Uncross-linked hyaluronic acid preparations ranging from 0.5 to
6 MDa, including hylan A, the ﬂuid component of hylan G-F 20, at
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inhibitory activity on IL-1 receptoreligand interactions. Surpris-
ingly, carboxymethylcellulose, which was included as a control for
viscosity, did show some inhibition of IL-1 binding to its receptor,
but even the highest concentration of 3mg/ml showed onlymodest
(39%) inhibition.
Rabbit OA model morphology and histology
Under gross morphologic examination, all rabbits receiving
ACLT surgery showed pathology indicative of OA development at all
time points evaluated, including lesions in AC and osteophyte
formation at joint margins [Fig. 3(A)]. Total osteophyte area at the
perimeter of the trochlear ridge (sum of medial and lateral regions)
was higher in OA joints than in sham controls at all time points. This
increase was less prominent (P ¼ 0.041) in hylan G-F 20-treated OA
joints compared with vehicle at 4 weeks post-injections [Fig. 3(B)].
Histologic examination of knees from the animals receiving
ACLT surgery revealed signs of cartilage degeneration including
ﬁbrillation, clefts, cloning and loss of proteoglycan [Fig. 4(A)].
Cartilage from hylan G-F 20-treated OA joints tended to be less
ﬁbrillated [Fig. 4(B)] and generally appeared subjectively thicker
than LRS-treated OA cartilage. Average Carlson scores of cartilageFig. 4. Hylan G-F 20 treatment improves osteoarthritic score of cartilage in the rabbit mode
ACLT model at 4 weeks post-surgery, immediately prior to initiation of treatment. a and b,
regions of chondrocyte loss, ﬁbrillation, clefting and decreased toluidine blue staining inte
treated (bottom row) cartilage 1 week after the ﬁnal injection. SB: subchondral bone.structure and proteoglycan content increased (worsened) in OA/
LRS animals over time compared with sham controls (P < 0.05). A
signiﬁcantly lower (better) Carlson cartilage structure score was
found in hylan G-F 20-treated OA cartilage than OA control groups
at 1 (P ¼ 0.005) and 4 weeks (P ¼ 0.028) after the ﬁnal injection
[Fig. 5(A)]. Examination of individual anatomic joint surfaces at
4 weeks showed considerable reductions in the scores of MFC and
lateral tibial plateau (LTP), but not those of the lateral femoral
condyle (LFC) or medial tibial plateau (MTP) from the hylan G-F 20-
treated OA group [Fig. 5(B)]. These effects of hylan G-F 20 on
cartilage were not observed at 8 weeks. The Carlson scores of
cartilage proteoglycan content in hylan G-F 20-treated OA joints
were comparable to LRS-treated OA joints at all time points
[Fig. 5(C)] and similar results were obtained after evaluating indi-
vidual joint surfaces.
Mean [standard deviation (SD)] total joint cartilage area
measurements (sum of all four compartments assessed/joint) are
shown in Fig. 6. Hylan G-F 20 consistently increased total
cartilage area compared with LRS, however, these data did not
reach statistical signiﬁcance (P ¼ 0.066). Summing the
measurements for the greatest thickness in each of the four
sections also did not yield any signiﬁcant differences among
groups (data not shown).l of OA. (A) Histological images showing osteoarthritic lesions of cartilage in the rabbit
H&E; c and d, toluidine blue. a and c, Sham/LRS. b and d, ACLT/LRS. Brackets identify
nsity. (B) Representative histology images of LRS-treated (top row) and hylan G-F 20-
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Col2A1 mRNA was detected in AC from sham, OA and hylan-
treated OA animals. The expression levels were signiﬁcantly
higher (P < 0.05) in hylan-treated OA cartilage compared with OA
controls [Fig. 7(A)]. Col II immunoreactivity was detected in hyaline
cartilage surfaces, calciﬁed cartilage within the trabecular bone,Fig. 5. Hylan G-F 20 improves cartilage structure integrity, but does not affect cartilage
proteoglycan loss in vivo. The integrity of AC was evaluated with the Carlson score
based on the extent of ﬁbrillation, clefting and loss of cartilage (scale 0‒20) for: (A) the
whole joint (B) individual joint compartments at 4 weeks post-injections for the LFC,
MFC, LTP and MTP *P < 0.05 (C) The proteoglycan content was evaluated using the
Carlson scoring system (0‒16) for toluidine blue stained tissue sections. Data are
expressed as LS-means of scores  SD (n ¼ 8 animals/group).menisci, and the growth plate in femorotibial joints [Fig. 7(B)]. We
observed increased expression of Col II in regions of partial thick-
ness cartilage erosions, suggesting a repair mechanism associated
with OA development [Fig. 7(Beb)]. In areas of full-thickness
cartilage ulcerations that were replaced by ﬁbrous-like tissue,
staining of Col II was often reduced or absent [Fig. 7(Bec)].
Comparedwith sham controls, therewas a signiﬁcant net reduction
in Col II staining in OA cartilage [P < 0.05; Fig. 7(C)]. Hylan G-F 20-
treated OA cartilage had less of a reduction in Col II levels than
vehicle-treated controls (4.4% vs 10.7%), but this difference did
not achieve statistical signiﬁcance.
MMP-13 mRNA expression dramatically increased in both
treated and untreated OA cartilage by >10-fold compared with
sham/LRS animals [Fig. 8(A)]. In a preliminary gene proﬁling study
of the rabbit ACLT model of OA using microarray, we found that
MMP-16 mRNA levels were up-regulated in OA cartilage and
synovium (data not shown), which was consistent with published
results in OA patients21,22. Here, we conﬁrmed those ﬁndings, but
did not ﬁnd any signiﬁcant treatment effects of hylan G-F 20 on
MMP-16 expression [Fig. 8(B)]. IL-1b mRNA levels were undetect-
able in cartilage in control, OA, and OA hylan G-F 20-treated groups
(data not shown), which is consistent with published data with the
rabbit model23. Low levels of IL-1b mRNA were detected in the
synovium, but the levels were unaltered across the groups
[Fig. 8(C)].
Discussion
Our in vivo data from this study have shown that hylan G-F 20,
when administered in a course of three weekly injections, retards
the progression of cartilage degeneration in the rabbit ACLT model
of mild to moderate OA. The most notable effects identiﬁed in our
in vivo and in vitro models were marked up-regulation of Col2A1,
inhibition of osteophyte development, and a potential increase in
cartilage area in vivo, with GAG preservation and inhibition ofFig. 6. Treatment with hylan G-F 20 demonstrates a tendency toward increased
cartilage area. Slides were digitally scanned by an automated slide scanner at
a magniﬁcation of 4. The cartilage area was then manually traced out for each of the
four cartilage compartments present on the digital images based on a standardized
measurement protocol. Mean (SD) total joint cartilage area measurements (sum of all
four compartments assessed per joint) are shown for n ¼ 8 joints/treatment group.
P. Li et al. / Osteoarthritis and Cartilage 20 (2012) 1336e1346 1343IL-1b-induced MMP expression in vitro. Interestingly, our in vitro
and in vivo results were not consistent. The hylan G-F 20-induced
GAG preservation seen in vitro was not apparent by histologic
assessment in vivo, and MMP-13 expression with hylan G-F 20 was
different in the in vivo and in vitromodels. One possible explanation
for this is the fact that ongoing mechanical insult due to the ACLT
procedure in the in vivo situation may negate potential effects of
hylan G-F 20 on GAG retention and MMP-13 expression seen in
static culture systems. For in vitro experiments, we chose to use
a challenging therapeutic model to increase the rigor of our ﬁnd-
ings. We pre-stimulated bovine cartilage with IL-1â for 3 days in
culture before adding hylan G-F 20 and maintained IL-1â in culture
throughout the “therapeutic period” to closely mimic the clinical
situation. While IL-1â stimulation of joint cell and tissue cultures is
a well accepted and commonly used method to mimic OA in vitro,
there was very low expression of IL-1b in the rabbit OA model,
potentially limiting meaningful comparison between the speciﬁc
in vitro and in vivo models used here. A substantially lowerFig. 7. Hylan G-F 20 increases Col II gene expression and matrix composition in OA cartilage
mRNA levels in cartilage with rabbit-speciﬁc primers/probes. The data are expressed as fo
histochemistry with anti-Col II speciﬁc antibodies. a, sham/LRS; b and c, OA/LRS. Note an inc
indicative of a reparative response (40). Arrow head in c indicates lack of Col II staining in th
Col II immunostaining using computer-assisted digital microscopy image analysis. The dataexpression level of IL-1â has been reported in OA patient synovial
ﬂuid (average of approximately 28 pg/ml)24 than is typically used in
culture to mimic the disease (5e10 ng/ml). It is possible that using
lower concentrations of IL-1â in culture may more accurately
reﬂect the human OA situation, but that was not tested here.
Cross-reactivity of commercially available kits for MMP-1, -3,
and -13 with the corresponding rabbit MMPs has also been prob-
lematic. However, effective rabbit-speciﬁc primer/probe sets for
MMP-1 and -3 were not available at the time these experiments
were performed. Based on these challenges and our preliminary
microarray analysis, we investigated MMP-13 and -16 gene
expression in the rabbit model, and defaulted to the more generally
studied MMP-1, -3, and -13 for the human and bovine explant
samples. While both in vitro and in vivo models have signiﬁcant
strengths, neither is a perfect model for the naturally occurring
human disease, thus, we consider them complementary, with the
preponderance of data from both models supporting both pro-
anabolic and anti-catabolic effects of hylan G-F 20 treatment.at 1 week after a series of three weekly injections. (A) Real-time PCR analysis of Co2A1
ld change over sham/LRS as baseline (n ¼ 8 animals/treatment group). (B) Immuno-
reased Col II staining intensity in region of erosion as indicated by arrows in b, possibly
is ulcerated region replaced by ﬁbrous-like tissues. (C) Quantiﬁcation of the intensity of
were expressed as percentage change over control sham/LRS (n ¼ 8/treatment).
P. Li et al. / Osteoarthritis and Cartilage 20 (2012) 1336e13461344Further research is warranted and is ongoing in our laboratory to
identify a potential unifying upstream mechanism by which these
effects are mediated.
Overall, our data support those of Marshall et al.9 using hylan G-
F 20 in a bilateral canine ACLTmodel with partial neurectomy, those
of others using similar products, and the few clinical evaluations
that have evaluated chondroprotection with HA. The chon-
droprotective effects of hylan G-F 20 were observed in the present
study at 1 and 4 weeks, but not at 8 weeks following the last
injection. However, the reduction of OA knee pain with hylan G-F
20 has been shown to last over 6 months in some patients25. This
relatively longer-lasting pain relief and shorter-term chon-
droprotection suggest that the effect on OA pain and cartilage
degeneration in the disease involve different cellular and/or
molecular mechanisms26. Since the residence time of hylan G-F 20A MMP-13
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Fig. 8. Up-regulated MMP-13 and -16 expression in OA cartilage was unaffected by
hylan G-F 20 in vivo. Expression levels of MMP-13 (A) and, MMP-16 (B) in the cartilage
and of IL-1b (C) in the synovium were determined by real-time PCR with rabbit-
speciﬁc primers/probes 1 week after the last injection. Data were normalized to
internal controls and expressed as means of fold change over the average of
baseline  SD (n ¼ 8).in normal goat joints is between 28 and 56 days27, we could
speculate that hylan G-F 20 may need to be present in the joint for
chondroprotective effects, but not necessarily for analgesic effects.
Volume and concentrationeeffect relationships of hylan G-F 20 are
also the subject of current study in our laboratory, as further
understanding of the effect of these parameters on analgesic and
structural outcomes in OA is warranted.
Consistent with the results of our studies, for the most part,
other investigators have shown that HA has multiple biologic
actions, which may contribute to its chondroprotective effects.
Some of the effects include enhancing extracellular-matrix syn-
thesis28e30, suppressing proteoglycan loss31, inhibiting expression
of matrix-degrading enzymes6,13,32,33, reducing production of
proinﬂammatory mediators34,35, and preventing chondrocyte
apoptosis36,37. HA has also been shown to interact with its receptors
on chondrocytes, CD4438,39 and intracellular adhesion molecule-1
(ICAM-1)40,41. Studies by Julovi and colleagues demonstrated that
HA inhibits IL-1b-mediated MMP production by interacting with
CD44 on chondrocytes42,43. These authors also demonstrated thatHA
with an intermediate molecular weight of 800 kDa penetrates oste-
oarthritic cartilage in vitro and is localized in the pericellular matrix
around chondrocytes. Whether highmolecular weight HA (>2MDa)
penetrates cartilage and binds to HA receptors on chondrocytes is
largely unknown. Infrequent uptake of hylan A (6e8 million Dalton)
by superﬁcial articular chondrocytes has been demonstrated in
normal goat joints in vivo27. It is possible that high molecular weight
HA may readily penetrate damaged and thus more permeable
cartilage in vivo under pathological conditions of OA. Taken together,
HA likely plays a biologic role by binding to its receptors on chon-
drocytes and triggering signaling pathways. Receptor-ligand inter-
action studies in vivowould be valuable in this regard.
In this study, macroscopic examination revealed a reduction in
osteophyte formation (bony outgrowths at joint margins) at the
4-week time point after hylan G-F 20 injections. The role of
osteophytes in OA development is controversial. Absence of
osteophytes has been linked to a higher risk of disease progression
in patients with hip OA44, suggesting that osteophyte formation
may represent an adaptive response to compensate for joint
instability, and thus help to redistribute forces to protect the
cartilage. However, preclinical studies of a murine OA model
showed a positive correlation between cartilage destruction and
degrees of osteophyte formation45, suggesting osteophytes may be
an indicator of more severe disease. Our ﬁndings of decreased
osteophyte formation and cartilage destruction support the latter
hypothesis. Interestingly, osteophyte formation in knee joints is
associated in a number of investigations with OA joint pain clini-
cally and is a more accurate predictor of pain progression than the
rate of joint space narrowing, an indicator of cartilage damage46. It
is possible that osteophytes contribute to OA pain by mechanical
impact on the innervated joint tissues such as the synovium,
capsule, ligament insertion sites, and meniscus. Consequently, it is
possible that hylan G-F 20 may relieve OA pain in part by reducing
osteophyte formation. More preclinical and clinical studies will be
needed to test this hypothesis.
Disease-modifying drugs for OA (DMOADs) are deﬁned as those
that may prevent the development of OA, and/or prevent, retard,
reverse, or stabilize the progression of established OA by altering
the underlying pathologic processes47. Currently, no therapeutic
has been approved for this indication. Development of drugs in this
category has been challenging in the ﬁeld due to the unknown
etiology and multifactorial nature of the disease. Data from this
study have added further evidence supporting the notion of
structure modifying activity of viscosupplementation48,49 using an
ultra-high molecular weight cross-linked preparation. The early
detection of Col2A1 up-regulation and preservation of cartilage
P. Li et al. / Osteoarthritis and Cartilage 20 (2012) 1336e1346 1345integrity that persists through, but apparently not beyond, the
residence time of 4 weeks suggests that repeat courses of IA
injections, or treatment with HA having a longer residence time,
may provide better and/or longer disease modiﬁcation efﬁcacy.
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